American Association for Cancer Research

Table 2.

Increased antitumor activity of vaccine plus docetaxel

Treatment	n	Tumor volume (day 37; mm³)	P = (vs:)
Treatment	n	Tumor volume (day 37; mm³)				None	Docetaxel	Vaccine	Vaccine + docetaxel
None	13	2038 ± 232	—	0.76	0.12	0.003
Docetaxel	14	2199 ± 409	0.76	—	0.197	0.030
Vaccine	13	1575 ± 107	0.12	0.197	—	0.036
Vaccine + docetaxel	15	1206 ± 85	0.003	0.030	0.036	—

Treatment	n	Tumor volume (day 37; mm³)	P = (vs:)
Treatment	n	Tumor volume (day 37; mm³)				None	Docetaxel	Vaccine	Vaccine + docetaxel
None	13	2038 ± 232	—	0.76	0.12	0.003
Docetaxel	14	2199 ± 409	0.76	—	0.197	0.030
Vaccine	13	1575 ± 107	0.12	0.197	—	0.036
Vaccine + docetaxel	15	1206 ± 85	0.003	0.030	0.036	—

NOTE: CEA-Tg mice were implanted s.c. with MC38-CEA⁺ tumors on day 0. Mice were either not treated (none), treated with docetaxel alone, vaccine alone, or first vaccinated and then treated with docetaxel (Fig. 5). Shown is average group tumor volumes at day 37. Bold numbers indicate statistical significance (P < 0.05).

View Large

This Feature Is Available To Subscribers Only